The present invention relates to the field of cancer therapy. In particular, the present invention relates to a method of preventing, treating or inhibiting the development of tumours and/or metastases in a subject by administering one or more immunomodulators into the skin via a microneedle device.

The present invention relates to the pulmonary delivery of antibodies or antibody derivatives.

The present invention provides a pharmaceutical composition comprising the therapeutic peptide CyPep-1, for use in treating neoplastic lesions, in particular warts.

Provided herein are compositions including methylene bis[4,4′-(2-chlorophenylureidophenoxyisobutyric acid)] (LR-90) or a pharmaceutically acceptable salt or derivative thereof and methods of use thereof for treating and/or preventing chemotherapy-induced neuropathic pain in a subject in need thereof.

The present invention relates to a sterile buffered eye topical composition containing metabolites of the fermentation of Lactobacillus pertaining to the species casei or paracasei and for ophthalmic use of the composition in the prevention or treatment of microbial eye infections, eye allergies, vernal keratoconjunctivitis and keratoconjunctivitis sicca and blepharitis.

The invention relates to a pharmaceutical composition comprising elafibranor, GFT1007 or a pharmaceutically acceptable salt of elafibranor or of GFT1007, for use to treat primary biliary cholangitis (PBC) without provoking and/or worsening at least one adverse event associated to PBC.

Disclosed is a peramivir dry powder inhaler, comprising a peramivir API or its acceptable salt or hydrate, wherein a single-dose preparation has a content of 5˜30 mg; the particle size distribution D10 of the dry powder is 1.3˜2.2 μm, D50 is 3˜6 μm, and D90 is 6˜13 μm. The peramivir dry powder inhaler prepared can effectively lower the titer of the influenza A virus in mouse lungs, has a notable anti-virus effect, can significantly prolong survival time and reduce mortality rate. The drug efficacy of the peramivir dry powder inhaler is superior to those of the peramivir sodium chloride injection and oseltamivir phosphate. The peramivir dry powder inhaler has a specific lung targeting effect, with notable improvement in drug effectiveness and safety.

The present invention relates to a biotin moiety-conjugated polypeptide and a pharmaceutical composition for oral administration comprising the same, wherein the polypeptide according to the present invention has an excellent in vivo oral bioavailability.

Disclosed are methods for treating insomnia, comprising administering orally a dosage form comprising Lemborexant or a pharmaceutically acceptable salt thereof to a patient in need thereof at a single daily dose ranging from 5 mg to 10 mg of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof, provided that the maximum dose is 5 mg once per day of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof when the patient has moderate hepatic impairment classified in Child-Pugh class B under Child-Pugh Classification.

The present invention provides, among other things, effective methods and compositions for delivering messenger RNA (mRNA) via rectal delivery. The present invention is, in part, based on unexpected observation that mRNA may be effectively delivered to the circulation, liver, kidney, colon and/or rectum via rectal delivery despite the barriers such as RNase and mucus layer.